Starling Oncology (STLNW) Net Cash Flow (2020 - 2026)

Starling Oncology (STLNW) has reported Net Cash Flow for 7 consecutive years, with $10.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 214.47% year-over-year to $10.8 million; the trailing twelve-month figure through Jun 2026 stood at $10.8 million (up 270.97% YoY), and the FY2025 full-year result was -$16.1 million, down 199.52% from the prior year.
• Net Cash Flow rose to $10.8 million in Q2 2026 per STLNW's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $13.6 million in Q2 2023 and bottomed at -$47.4 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$4.1 million across 5 years, with a median of -$494000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 908.99% in 2024, then tumbled 2660.16% in 2025.
• Over 5 years, Net Cash Flow stood at -$47.4 million in 2022, then surged by 112.56% to $6.0 million in 2023, then plunged by 65.04% to $2.1 million in 2024, then surged by 183.85% to $5.9 million in 2025, then soared by 83.07% to $10.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $10.8 million, -$3.3 million, and $5.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.